BACKGROUND/AIM: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. PATIENTS AND METHODS: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. RESULTS: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. CONCLUSION: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.

3rd Faculty of Medicine Charles University Department of Oncology Prague Czech Republic

Department of General Surgery University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Oncology University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Oncology University Hospital Kralovske Vinohrady Prague Czech Republic;

Zobrazit více v PubMed

Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current clinical strategies of pancreatic cancer treatment and open molecular questions. Int J Mol Sci. 2019;20(18):4543. doi: 10.3390/ijms20184543. PubMed DOI PMC

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763. PubMed DOI

Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708. PubMed DOI PMC

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. PubMed DOI

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi: 10.1056/NEJMoa1304369. PubMed DOI PMC

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923. PubMed DOI

Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O’Reilly EM. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272–1281. doi: 10.1016/S0140-6736(23)01366-1. PubMed DOI PMC

McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 2008;22(1):65–73. doi: 10.1016/j.bpg.2007.11.007. PubMed DOI

Hanahan D, Weinberg RA. Hallmarks of Cancer: The next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. PubMed DOI

Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059. PubMed DOI

Dell’Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. Oncotarget. 2020;11(10):924–941. doi: 10.18632/oncotarget.27518. PubMed DOI PMC

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: a propensity score analysis. Gastroenterol Res Pract. 2018;2018:2373868. doi: 10.1155/2018/2373868. PubMed DOI PMC

McLellan P, Henriques J, Ksontini F, Doat S, Hammel P, Desrame J, Trouilloud I, Louvet C, Pietrasz D, Vernerey D, Bachet JB. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Clin Res Hepatol Gastroenterol. 2021;45(3):101541. doi: 10.1016/j.clinre.2020.08.016. PubMed DOI

Elias R, Cockrum P, Surinach A, Wang S, Chul Chu B, Shahrokni A. Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncologist. 2022;27(6):469–475. doi: 10.1093/oncolo/oyac028. PubMed DOI PMC

King G, Ittershagen S, He L, Shen Y, Li F, Villacorta R. Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world. Adv Ther. 2022;39(12):5433–5452. doi: 10.1007/s12325-022-02317-9. PubMed DOI PMC

Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Eur J Cancer. 2021;151:3–13. doi: 10.1016/j.ejca.2021.03.040. PubMed DOI

Orlandi E, Citterio C, Anselmi E, Cavanna L, Vecchia S. FOLFIRINOX or gemcitabine plus nab-paclitaxel as first line treatment in pancreatic cancer: a real-world comparison. Cancer Diagn Progn. 2024;4(2):165–171. doi: 10.21873/cdp.10303. PubMed DOI PMC

Rho YS, Ranger J, Hamalova S, Barrera I, Mamo A, Batist G, Kavan P. Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:v258. doi: 10.1093/annonc/mdx369.137. DOI

Lin S, Fang Y, Mo Z, Lin Y, Ji C, Jian Z. Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients. World J Surg Oncol. 2020;18(1):186. doi: 10.1186/s12957-020-01962-0. PubMed DOI PMC

Takeuchi M, Mitsuyoshi M, Yoshida K, Onoda M, Iwamura M, Furutani A, Kawano K, Katoh T. The Lymphocyte-to-monocyte ratio is an independent prognostic indicator in pancreatic head cancer that correlates with obstructive jaundice. Anticancer Res. 2020;40(6):3371–3377. doi: 10.21873/anticanres.14320. PubMed DOI

Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, Liu L, Meng Z, Wang P, Chen Z. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi: 10.1002/cncr.30057. PubMed DOI

Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254–264. doi: 10.1016/j.pan.2019.12.010. PubMed DOI

Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Hirayama Y, Hieda N, Yoshida T, Okuno N, Shimizu Y, Niwa Y, Yamao K. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology. 2016;16(5):859–864. doi: 10.1016/j.pan.2016.05.007. PubMed DOI

Meng Q, Shi S, Liang C, Liang D, Xu W, Ji S, Zhang B, Ni Q, Xu J, Yu X. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:4591–4598. doi: 10.2147/OTT.S145708. PubMed DOI PMC

Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197–203. doi: 10.1016/j.amjsurg.2009.08.041. PubMed DOI

An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15(6):516–522. doi: 10.3109/1354750X.2010.491557. PubMed DOI

Aoyama T, Maezawa Y, Hashimoto I, Rino Y, Oshima T. Clinical impact of nutrition and inflammation assessment tools in pancreatic cancer treatment. Anticancer Res. 2023;43(9):3849–3860. doi: 10.21873/anticanres.16572. PubMed DOI

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to Lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: a propensity score analysis. Gastroenterol Res Pract. 2018;2018:2373868. doi: 10.1155/2018/2373868. PubMed DOI PMC

Kawahara S, Aoyama T, Murakawa M, Kanemoto R, Takahashi D, Kamioka Y, Hashimoto I, Kamiya M, Kato A, Maezawa Y, Kazama K, Sawazaki S, Tamagawa H, Kobayashi S, Ueno M, Yamamoto N, Oshima T, Yukawa N, Rino Y, Saito A, Morinaga S. Clinical impact of preoperative neutrophil-to-lymphocyte ratio in surgical patients with pancreatic cancer. Anticancer Res. 2024;44(1):221–228. doi: 10.21873/anticanres.16805. PubMed DOI

Lebenthal JM, Zheng J, Glare PA, O’Reilly EM, Yang AC, Epstein AS. Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. Cancer. 2021;127(10):1568–1575. doi: 10.1002/cncr.33420. PubMed DOI PMC

Ma LX, Wang Y, Espin-Garcia O, Allen MJ, Jang GH, Zhang A, Dodd A, Ramotar S, Hutchinson S, Tehfe M, Ramjeesingh R, Biagi J, Wilson JM, Notta F, Fischer SE, Zogopoulos G, Gallinger S, Grant RC, Khokha R, Chan N, Grünwald BT, Knox JJ, O’Kane GM. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Br J Cancer. 2023;128(10):1916–1921. doi: 10.1038/s41416-023-02214-0. PubMed DOI PMC

Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, Sharma R, Small D. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010;17(4):52–58. doi: 10.3747/co.v17i4.567. PubMed DOI PMC

Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The Prognostic Index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection. Ann Surg Oncol. 2020;27(6):2017–2024. doi: 10.1245/s10434-019-08161-6. PubMed DOI PMC